Biopeople

From Veep to President

From Veep to President

05.05.2015 - The Faculty of Pharmaceutical Medicine has reinforced its top ranks with the appointment of Professor Alan Boyd as its new President. Alan who is currently Vice President of the faculty, will take up office later this year on 19th November replacing Dr Keith Bragman who will have served a three-year term.

Alan is owner of Boyds consultancy business and began his pharmaceutical career 28 years ago at Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later taking on the role of Director of Clinical and Medical Affairs at ICI Pharma in Canada. In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In April 2005, he left to set up Alan Boyd Consultants Ltd. The focus of the consultancy is to aid and support early stage life science based companies.

Alan is a graduate in Biochemistry and Medicine from the University of Birmingham. His experience will ensure that the Faculty will help further establish its role as a healthcare partner and in the outside world.

http://www.european-biotechnology-news.com/people/bio-people/2015/alan-boyd.html

23.01.2015 Filipe Gaspar has been appointed Vice President of Research and Development at the Portuguese pharmaceutical ingredient manufacturer Hovione.

© Hovione

The chemical engineer has worked at Hovione for the last eleven years, mostly in particle engineering, but most recently in a business development role. Gaspar is co-author and co-inventor of numerous publications, scientific presentations and patents.

“For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver,” commented Hovione CEO Guy Villax.

21.01.2015 Fredrik Lindgren is the new CEO and president of Swedish clinical stage drug development company Hansa Medical.

© Hansa Medical

He replaces Emanuel Björne, who has led the company since it was established and takes over the role of Corporate Development Director. Lindgren, who holds a law degree from Lund University, has previously held the position of CEO at Karo Bio and Biolin Scientific. He is chairman and member of the board of Prostalund, Larodan Fine Chemicals and Exini Diagnostics.

19.01.2015 Slovenian chemist Tina Trdan Lušin has been honoured with the Pregl Award for outstanding doctoral work, a price annually conferred by the National Institute of Chemistry Slovenia.

© Pliva

Lušin, a researcher at the Sandoz Development Center, studied pharmacogenetic aspects of metabolism and transport of selective estrogen receptor modulators. With her work, the award committee said, Lušin "established the reason for inter-individual variability in the response to selective estrogen receptor modulators and thereby gained new information for treatment, which could be used in clinical practice."

15.01.2015 On 15 December 2014 Moberg Pharma AB welcomed Jeff Vernimb as its new General Manager for its US operations. He also became a member of the Swedish pharmaceutical company’s Management Team.

© Moberg Pharma

With more than 25 years of experience in consumer health products marketing and sales across multi-national and smaller entrepreneurial businesses, Jeff will help increase the Stockholm-based company’s US business. Prior to joining Moberg, Jeff was Vice President of sales and a member of the senior management team with Insight Pharmaceuticals. In addition to his position at Insight, he has held senior level positions at Dynova Laboratories, Cardinal Health, Novartis Consumer and Pfizer/Warner Lambert.

“It is a pleasure to welcome Jeff to the Management Team at Moberg. I look forward to working together to continue driving the growth of our US business,” said Peter Wolpert, CEO of Moberg Pharma AB.

13.01.2014 French biopharma Pharnext has nominated pharmaceutical and biotechnology industry executive Michel de Rosen to its Board of Directors as it sets its sights on expanding the company’s new therapeutics development, both nationally and internationally.

© Pharnext

Michel de Rosen has a wealth of experience in the sector, holding various executive positions for nearly 25 years at Rhone-Poulenc, in particular its pharmaceutical subsidiary Rhone-Poulenc Rorer, now known as Sanofi. While at Rhone-Poulenc, from 1983 to 1999, Michel served as president and CEO of Pharmuka, Rhone-Poulenc Fibers and Polymers, and then Rhone-Poulenc in the US. Post Rhone-Poulenc, he was CEO of ViroPharma, which was bought by Shire in 2014. After 15 years in the States, Michel returned to France and has been CEO of Eutelsat Communications since 2009.

“Michel de Rosen’s nomination to our board falls within our wish to accelerate Pharnext’s development both in France and abroad. His international expertise will prove valuable to us in our development dynamics,” said Daniel Cohen, chairman and CEO of Pharnext.

06.01.2014 Belgian Biotech FlandersBio has appointed Erwin Blomsma as its new chairman to continue the development of the company’s new strategy, which it intends to roll out both locally and globally.

© Okapi

Erwin started his career after a post-doctoral study at the University of Leuven in Belgium at Janssen Pharmaceutica in 1996 as Technology Manager. In 2000, he co-founded a contract research organisation Crystallice, which was later absorbed by another CRO, Avantium Technologies, where he became VP Technology in 2001 and COO in 2004. In 2007, Dr Blomsma co-founded and became CEO of Okapi Sciences, a company focused on animal health. Okapi Sciences developed a healthy pipeline of veterinary drugs, one of which was licensed to Novartis Animal Health in 2013. Since March 2014, he has been the general manager of Aratana Therapeutics NV in Leuven and VP of Aratana Therapeutics Inc.

“I am honoured to take up the task to lead FlandersBio into a next stage of growth and expansion,” said Erwin. “We will fully continue to develop the synergies with micro-electronics, ICT, medical technology and novel industrial and food applications in this further growth.”

29.12.2014 Chemist-by-training Sue Harris has been appointed as a non-Executive Director on the board of Abcam plc, a UK-based biotech company.

© Abcam plc

Harris has over 30 years of experience in financial and commercial roles. She held senior executive roles at Marks & Spencer, Standard Life and most recently worked as Finance Director at Lloyds Banking Group. Sue is a Member of the Audit and Assurance Council of the Financial Reporting Council and previously was a Non-Executive Director on the Board of St. James’s Place and a Member of the Audit and Remuneration Committee of the British Bankers’ Association.

19.12.2014 Gil Beyen has been appointed independent director of Belgian biotech Novadip Biosciences, a spin-off from Louvain University and Saint-Luc University Hospital active in skeletal regenerative medicine.

© Novadip Biosciences

Beyen is currently CEO and chairman of Erytech Pharma. Before that he served as CEO of French biotech Tigenix, which he also co-founded. In this capacity, he led the development and regulatory approval of ChondroCelect, the first Advanced Therapy Medicinal Product in Europe. He was also instrumental in the listing of the company and the subsequent merger with Cellerix. Beyen holds an MSc in Bio-Engineering from the University of Leuven and obtained an MBA from the University of Chicago in 1990.

09.12.2014 Belgian Ablynx NV welcomed Johan Heylen as its new Chief Commercial Officer. The Flemish drug developer announced the cast in mid-November.

© Ablynx

Heylen will assume responsibility for all commercial activities. Having more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth, he most recently was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at pharma heavyweight GSK. At GSK, Heylen was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Heylen led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix, Priorix and Varilrix, which together achieved sales of more than €1.5bn. "He will also bring valuable expertise to our business development team as we seek to develop our relationships with pharmaceutical companies around the world,” expects Edwin Moses, CEO of Ablynx. 

With Heylen at the steering wheel, Ablynx is now ready to board the market with its nanobodies. This summer, the antibody specialist managed to raise €41.7m through a private placement of new shares.

08.12.2014 Clinical stage biopharma firm Intercept Pharmaceuticals, focused on therapeutics to treat chronic liver and intestinal diseases, has appointed Lisa Bright as Senior Vice President and Head of Europe.

© Lazar Partners

The NASDAQ-listed company announced the news in mid-November when the appointment became effective. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London. She brings in more than 25 years of biotech and pharmaceutical industry experience – and she has all the necessary knowledge about liver diseases. As a Vice President at Gilead Sciences she was in charge of the Launch Planning for Europe, Asia, Middle East and Australasia of hepatitis drug Sovaldi. At Gilead, she held positions of increasing responsibility, including Vice President Northern Europe and Vice President Head Government Affairs for Europe, Middle East and Australasia. Bright's leadership of Sovaldi's European launch contributed to the most successful product launch in pharmaceutical history, Intercept pronounced.

Vorherige Seite3/25Nächste Seite

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Stock list

All quotes

TOP

  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%

TOP

  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%

FLOP

  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%

TOP

  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%

FLOP

  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015

Current issue

All issues